Scalability and sustainability in stem cell manufacturing. We initiate coverage on Cynata Therapeutics Ltd. with a Buy rating and 12-month price target of A$1.00 per share. Cynata is an Australian stem cell-focused firm with a proprietary platform, CymerusTM, which provides a high-throughput, sustainable solution for the production of mesenchymal stem cells (MSCs).
Cynata Initiation Report
Manufacturing validated for Therapeutic Scale-Up consistent, reproducible stem cells in unlimited quantities!
Analyst: Russell Wright
Initiation of Coverage: “Unlimited quantities of potent adult stem cells, no hassles”
Analyst: Stuart Roberts